Title: CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric
intestinal metaplasia
Version: 0 Date: 08 Sep 2021
Reviewer's report:
This study indicated that CD10 was a excellent biomarker with high sensitivity and specificity
for complete IM. And Das1 was a biomarker with high specificity for incomplete IM. In addition,
positive Das1 staining indicated high risk of progression, especially for complete IM.
However, lots of studies have demonstrated the roles of CD10[1,2] and Das1[3-7] in IM subtypes
and the progression of IM to GC. So their is lack of innovation in this study.
References:
1. Histopathological differences in the development of small intestinal metaplasia between
antrum and body of stomach. Pathol Res Pract. 2005;201(7):487-96.
2. Incidence and distribution of hybrid goblet cells in complete type intestinal metaplasia of the
stomach. Pathol Res Pract. 2005;201(1):11-9.
3. Mirza ZK, Das KK, Slate J, et al. Gastric intestinal metaplasia as detected by a monoclonal
antibody is highly associated with gastric adenocarcinoma. Gut. 2003;52:807-812.
4. Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett’s esophagus and intestinal
metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical
study of cytokeratins 7 and 20, Das-1 and 45MI. Am J Surg Pathol. 2001;25:87-94.
5. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and Das-1 immunostaining
reveal similarities among cardiac mucosa, CIM, and Barrett’s esophagus. Am J Gastroenterol.
2002;97:2514-2523.
6. Piazuelo MB, Haque S, Delgado A, et al. Phenotypic differences between esophageal and
gastric intestinal metaplasia. Mod Pathol. 2004;17:62-74.
7. Watari J, Das KK, Amenta PS, et al. Effect of eradication of Helicobacter pylori on the
histology and cellular phenotype of gastric intestinal metaplasia. Clin Gastroenterol Hepatol.
2008;6:409-417.
Title: CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric
intestinal metaplasia
Version: 0 Date: 08 Sep 2021
Reviewer's report:
This study indicated that CD10 was a excellent biomarker with high sensitivity and specificity
for complete IM. And Das1 was a biomarker with high specificity for incomplete IM. In addition,
positive Das1 staining indicated high risk of progression, especially for complete IM.
However, lots of studies have demonstrated the roles of CD10[1,2] and Das1[3-7] in IM subtypes
and the progression of IM to GC. So their is lack of innovation in this study.
References:
1. Histopathological differences in the development of small intestinal metaplasia between
antrum and body of stomach. Pathol Res Pract. 2005;201(7):487-96.
2. Incidence and distribution of hybrid goblet cells in complete type intestinal metaplasia of the
stomach. Pathol Res Pract. 2005;201(1):11-9.
3. Mirza ZK, Das KK, Slate J, et al. Gastric intestinal metaplasia as detected by a monoclonal
antibody is highly associated with gastric adenocarcinoma. Gut. 2003;52:807-812.
4. Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett’s esophagus and intestinal
metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical
study of cytokeratins 7 and 20, Das-1 and 45MI. Am J Surg Pathol. 2001;25:87-94.
5. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and Das-1 immunostaining
reveal similarities among cardiac mucosa, CIM, and Barrett’s esophagus. Am J Gastroenterol.
2002;97:2514-2523.
6. Piazuelo MB, Haque S, Delgado A, et al. Phenotypic differences between esophageal and
gastric intestinal metaplasia. Mod Pathol. 2004;17:62-74.
7. Watari J, Das KK, Amenta PS, et al. Effect of eradication of Helicobacter pylori on the
histology and cellular phenotype of gastric intestinal metaplasia. Clin Gastroenterol Hepatol.
2008;6:409-417.
Please review this paper.
user
Title: CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric
intestinal metaplasia
Version: 0 Date: 08 Sep 2021
Reviewer's report:
This study indicated that CD10 was a excellent biomarker with high sensitivity and specificity
for complete IM. And Das1 was a biomarker with high specificity for incomplete IM. In addition,
positive Das1 staining indicated high risk of progression, especially for complete IM.
However, lots of studies have demonstrated the roles of CD10[1,2] and Das1[3-7] in IM subtypes
and the progression of IM to GC. So their is lack of innovation in this study.
References:
1. Histopathological differences in the development of small intestinal metaplasia between
antrum and body of stomach. Pathol Res Pract. 2005;201(7):487-96.
2. Incidence and distribution of hybrid goblet cells in complete type intestinal metaplasia of the
stomach. Pathol Res Pract. 2005;201(1):11-9.
3. Mirza ZK, Das KK, Slate J, et al. Gastric intestinal metaplasia as detected by a monoclonal
antibody is highly associated with gastric adenocarcinoma. Gut. 2003;52:807-812.
4. Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett’s esophagus and intestinal
metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical
study of cytokeratins 7 and 20, Das-1 and 45MI. Am J Surg Pathol. 2001;25:87-94.
5. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and Das-1 immunostaining
reveal similarities among cardiac mucosa, CIM, and Barrett’s esophagus. Am J Gastroenterol.
2002;97:2514-2523.
6. Piazuelo MB, Haque S, Delgado A, et al. Phenotypic differences between esophageal and
gastric intestinal metaplasia. Mod Pathol. 2004;17:62-74.
7. Watari J, Das KK, Amenta PS, et al. Effect of eradication of Helicobacter pylori on the
histology and cellular phenotype of gastric intestinal metaplasia. Clin Gastroenterol Hepatol.
2008;6:409-417.
assistant